FibroBiologics
FBLG
18 hedge funds and large institutions have $291K invested in FibroBiologics in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 31 closing their positions.
127% more capital inflows, than outflows
Capital inflows: $858K | Capital outflows: $378K
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0.36% less ownership
Funds ownership: 6.64% → 6.28% (-0.36%)
61% less funds holding
Funds holding: 46 → 18 (-28)
87% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fund Evaluation Group
Cincinnati,
Ohio
|
+$308K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$72.4K |
| 3 |
Renaissance Technologies
New York
|
+$26.3K |
| 4 |
Cascade Financial Partners
San Diego,
California
|
+$4.16K |
| 5 |
BlackRock
New York
|
+$3.13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$64.9K |
| 2 |
Jane Street
New York
|
-$33.7K |
| 3 |
AMG National Trust Bank
Greenwood Village,
Colorado
|
-$31.3K |
| 4 |
State Street
Boston,
Massachusetts
|
-$25K |
| 5 |
Optivise Advisory Services
Franklin,
Tennessee
|
-$24.8K |
FBLG Hedge Fund Activity: Q1 2026 in Review
18 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in FibroBiologics (FBLG) for Q1 2026, worth a combined $291K — down 71% from $994K a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of FBLG and 4 opened new positions — a net loss of 27 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Fund Evaluation Group, opening a new position worth an estimated $308K. The largest seller was Millennium Management, exiting entirely with an estimated $64.9K sold.
- 18 institutional investors held FibroBiologics (FBLG) as of Q1 2026, down from 46 in Q4 2025.
- Funds reported $291K of FibroBiologics stock for Q1 2026, down 71% quarter-over-quarter.
- 4 funds opened new FibroBiologics positions in Q1 2026 and 31 closed out, a net change of -27 holders.
- The largest FibroBiologics buyer in Q1 2026 was Fund Evaluation Group, an estimated $308K added.
- The largest FibroBiologics seller in Q1 2026 was Millennium Management, an estimated $64.9K sold.
Based on aggregated 13F filings for Q1 2026.